# HARMONi-6 (NCT05840016)

> AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05840016
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Akeso
- Conditions: Advanced Squamous Non Small Cell Lung Cancer
- Interventions: AK112, Carboplatin, Paxlitaxel; Tislelizumab, Carboplatin, Paxlitaxel
- Enrollment: 532
- Primary outcome: PFS assessed by IRRC per RECIST v1.1

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses HARMONi-6’s comparison of ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in advanced squamous NSCLC, and the rationale of combining PD-1 and VEGF targeting. Questions raised include whether the overall-survival pattern will persist at final analysis, how findings may translate beyond the study population, and how to interpret the older-patient signal. Discussion also covers bleeding-related eligibility exclusions, including hemoptysis, cavitation and vessel involvement, and their implications for patient selection.

## Indexed commentary on HARMONi-6 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 134
- YouTube: 14
- Podcasts: 11
- Bluesky threads: 8
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=harmoni-6-nct05840016

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05840016", "email": "<work email>"}; the inbox owner confirms by the emailed link.